-
1كتاب إلكتروني
المؤلفون: Müller, CristinaAff2, van der Meulen, Nicholas P.Aff2, Aff3
المساهمون: Prasad, Vikas, editorAff1
المصدر: Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. :225-236
-
2كتاب إلكتروني
المؤلفون: Wilbur, D. ScottAff4
المساهمون: Lewis, Jason S., editorAff1, Windhorst, Albert D., editorAff2, Zeglis, Brian M., editorAff3
المصدر: Radiopharmaceutical Chemistry. :409-424
-
3دورية أكاديمية
المؤلفون: Cristina Müller, Josefine Reber, Stephanie Haller, Holger Dorrer, Ulli Köster, Karl Johnston, Konstantin Zhernosekov, Andreas Türler, Roger Schibli
المصدر: Pharmaceuticals, Vol 7, Iss 3, Pp 353-365 (2014)
مصطلحات موضوعية: terbium-149, alpha-therapy, folate receptor, DOTA-folate, KB tumors, 149Tb-cm09, albumin binder, radionuclide therapy, Medicine, Pharmacy and materia medica, RS1-441
وصف الملف: electronic resource
-
4
المؤلفون: Jan Andersson, Bryce J. B. Nelson, Frank Wuest
المصدر: Pharmaceutics, Vol 13, Iss 49, p 49 (2021)
Pharmaceuticsمصطلحات موضوعية: Radium-223, theranostics, thorium-227, radium-223, medicine.medical_treatment, Targeted radionuclide therapy, Pharmaceutical Science, lcsh:RS1-441, Review, actinium-225, 030218 nuclear medicine & medical imaging, lcsh:Pharmacy and materia medica, 03 medical and health sciences, 0302 clinical medicine, TheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITY, Medicine, targeted alpha therapy, Particle therapy, business.industry, Radiochemistry, terbium-149, Keywords: targeted alpha therapy, targeted radionuclide therapy, 030220 oncology & carcinogenesis, business, alpha particle therapy, bismuth-213, astatine-211, medicine.drug
-
5دورية أكاديمية
المؤلفون: Beyer, G.-J., Miederer, M., Vranješ-Đurić, S., Čomor, J. J., Künzi, G., Hartley, O., Senekowitsch-Schmidtke, R., Soloviev, D., Buchegger, F., and the ISOLDE CollaborationAff7
المصدر: European Journal of Nuclear Medicine and Molecular Imaging. April 2004 31(4):547-554
-
6
المساهمون: Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public), Laboratoire de physique subatomique et des technologies associées (SUBATECH), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), INCa-DGOS-Inserm_12558, ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), ANR-16-IDEX-0007,NExT (I-SITE),NExT (I-SITE)(2016), European Project: CA19114,NOAR, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Guérard, François, Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, NExT (I-SITE) - - NExT (I-SITE)2016 - ANR-16-IDEX-0007 - IDEX - VALID, COST Action NOAR 'Network for Optimized Astatine labeled Radio-pharmaceuticals' - NOAR - CA19114 - INCOMING
المصدر: Pharmaceutics
Pharmaceutics, MDPI, 2021, 13 (6), pp.906. ⟨10.3390/pharmaceutics13060906⟩
Pharmaceutics, Vol 13, Iss 906, p 906 (2021)
Pharmaceutics, 2021, 13 (6), pp.906. ⟨10.3390/pharmaceutics13060906⟩مصطلحات موضوعية: Radium-223, thorium-227, Computer science, [SDV]Life Sciences [q-bio], radium-223, Pharmaceutical Science, Alpha (ethology), Review, lead-212, actinium-225, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Pharmacy and materia medica, 0302 clinical medicine, medicine, Selection (genetic algorithm), targeted alpha therapy, terbium-149, α-emitters, 3. Good health, [SDV] Life Sciences [q-bio], RS1-441, 030220 oncology & carcinogenesis, Biochemical engineering, bismuth-213, astatine-211, Chemical design, bismuth-212, medicine.drug
وصف الملف: application/pdf
-
7
المؤلفون: Roger Schibli, Ulli Köster, Karl Johnston, Stephanie Haller, Cristina Müller, Josefine Reber, Konstantin Zhernosekov, Holger Dorrer, Andreas Türler
المصدر: Pharmaceuticals
Müller, Cristina; Reber, Josefine; Haller, Stephanie; Dorrer, Holger; Köster, Ulli; Johnston, Karl; Zhernosekov, Konstantin; Türler, Andreas; Schibli, Roger (2014). Folate Receptor Targeted Alpha-Therapy Using Terbium-149. Pharmaceuticals, 7(3), pp. 353-365. MDPI 10.3390/ph7030353 <http://dx.doi.org/10.3390/ph7030353>
Pharmaceuticals, Vol 7, Iss 3, Pp 353-365 (2014)
Pharmaceuticals; Volume 7; Issue 3; Pages: 353-365
'Pharmaceuticals ', vol: 7, pages: 353-365 (2014)
Pharmaceuticals, 7 (3)مصطلحات موضوعية: Pathology, medicine.medical_specialty, Health Physics and Radiation Effects, Other Fields of Physics, Pharmaceutical Science, Alpha (ethology), lcsh:Medicine, lcsh:RS1-441, Terbium-149, Alpha-therapy, Folate receptor, DOTA-folate, KB tumors, 149Tb-cm09, Albumin binder, Radionuclide therapy, Pharmacology, Group A, Article, 030218 nuclear medicine & medical imaging, lcsh:Pharmacy and materia medica, terbium-149, alpha-therapy, folate receptor, albumin binder, radionuclide therapy, 03 medical and health sciences, 0302 clinical medicine, Drug Discovery, 540 Chemistry, Medicine, business.industry, lcsh:R, In vitro toxicology, Acute toxicity, In vitro, 3. Good health, 030220 oncology & carcinogenesis, Cancer cell, Molecular Medicine, 570 Life sciences, biology, Specific activity, business
وصف الملف: application/pdf; application/application/pdf
-
8دورية أكاديمية
المساهمون: Van Ginneken, A
المصدر: Nucl. Phys. A196: No. 1, 156-60(1972).; Other Information: Orig. Receipt Date: 30-JUN-73
وصف الملف: Medium: X
URL الوصول: http://www.osti.gov/scitech/biblio/4597220
-
9دورية أكاديمية
المساهمون: Gromova, I
المصدر: Izv. Akad. Nauk SSSR, Ser. Fiz. 36: No. 10, 2118-2123(Oct 1972).; Other Information: Orig. Receipt Date: 30-JUN-73
وصف الملف: Medium: X
URL الوصول: http://www.osti.gov/scitech/biblio/4539096
-
10دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.